Navigation Links
Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR
Date:9/12/2013

Arbor. "As a specialty pharmaceutical company already focused in the cardiovascular area, we are well-positioned to ensure the EDARBI products are available to all appropriate patients who may need them."

About Hypertension
Hypertension, or high blood pressure, is a chronic medical condition in which blood pressure is elevated to levels of 140 mm Hg or greater systolic and/or 90 mm Hg or greater diastolic. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of blood pressure in individuals with severe hypertension can provide substantial benefit.

Hypertension impacts approximately 67 million Americans, or nearly one in three adults. It is estimated that nearly one billion people are affected by hypertension worldwide, and this figure is predicted to increase to 1.5 billion by 2025. Hypertension typically has no symptoms. Adults of all ages and backgrounds can develop hypertension; however, the risk of developing the condition increases with age, with more than half of people over age 60 affected. Hypertension is also costly to the nation's health care system. The American Heart Association recently estimated that direct and indirect expenses associated with hypertension cost the nation more than $73 billion in 2009.

About EDARBI and EDARBYCLOR
EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) developed by Takeda for the treatment of hypertension to lower blood pressure in adults. EDARBI lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone, which naturally exists within the body. When EDARBI blocks the angiotensin II receptor, blood vessels can stay relaxed and open, and blood pressure can be reduced. EDARBI is indicated for the treatment of hypertension to lower blood pressure in adults, either alone or in combination with other antihypertensive
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
2. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
3. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
4. Takeda Launches New Subsidiary in Peru
5. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
6. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
7. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
8. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
9. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
10. Takeda to Acquire Inviragen, Inc.
11. Takeda Responds to Verdict in Diabetes Drug Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... JACKSONVILLE, Fla. , March 3, 2015 /PRNewswire/ ... is pleased to announce the hiring of ... Sales to lead business development efforts and build ... years of experience in software development, sales, and ... of enterprise software applications. iTraycer is a comprehensive ...
(Date:3/3/2015)... LOUISVILLE, Ky. , March 3, 2015 ... Louisville,s greatest leaders in aesthetics. In ... successful Brownsboro Plastic and Hand Surgery practice, Dr. Cummins ... Louisville Tattoo Removal clinic . Dr. Cummins performs ... "I founded Louisville Tattoo Removal in order ...
(Date:3/3/2015)...   Clinical trials at Qilu ... Publications in peer reviewed journals Gastrointestinal Endoscopy ... value of confocal laser endomicroscopy in treatment of highly-prevalent ... Asia   ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced ...
Breaking Medicine Technology:Medical Tracking Solutions, Inc. Hires New SVP, Sales 2Surgeon Owned And Operated Louisville Tattoo Removal Offers Astanza Duality Laser Treatments 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4
... 2010 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... first time at the 52nd Annual Meeting of ... activity, safety and tolerability of perifosine in patients ... lymphoma (HL).  KRX-0401 (perifosine) is the Company,s novel, ...
... BOSTON, Dec. 6, 2010 PAREXEL International Corporation ... biopharmaceutical services provider, today announced that it has ... emerging regions for biopharmaceutical development.   PAREXEL,s ... Russia will support its clients in more effectively ...
Cached Medicine Technology:Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 2Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 3Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 4Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 5PAREXEL Opens Clinical Logistics Facilities in Singapore and Russia 2PAREXEL Opens Clinical Logistics Facilities in Singapore and Russia 3PAREXEL Opens Clinical Logistics Facilities in Singapore and Russia 4
(Date:3/3/2015)... On February 21st, the rooftop of the ... a day-long event that features a gathering of providers ... Organized by Debbie Durkin and Durkin Entertainment, Los Angeles’ ... EcoLuxe Lounge saw many notable attendees. Among them was ... The Flash, Star Trek: Deep Space Nine and many, ...
(Date:3/3/2015)... 03, 2015 Man, Woman & Student ... help find cures and ensure access to treatments for ... for patents and their families. Through this annual national ... the fight for a world without blood cancers. The ... in the country, to be announced this summer. To ...
(Date:3/3/2015)... 03, 2015 In March, 1% for ... will kick off a new campaign, “Know Your Source,” which ... nonprofits, and ambassadors in their quest for ingredient awareness and ... several of its members and partners, including King Arthur Flour, ... network, to raise awareness for food as an environmental issue, ...
(Date:3/3/2015)... 03, 2015 While it is clear ... reason why young Canadian drivers are signing up to ... value proposition to be enticed. Due to current regulations, ... very stripped-back form. Its full capability is starting ... tracking, predictive maintenance, emergency breakdown services are at the ...
(Date:3/3/2015)... MD (PRWEB) March 03, 2015 Today ... Association (ASHA) is using the occasion to applaud and ... campaign by the World Health Organization (WHO) for stemming ... campaign aims to encourage young people to practice safe ... audio technology, attending concerts or sporting events, or engaging ...
Breaking Medicine News(10 mins):Health News:Hollywood Star Chase Masterson and Choices Recovery Discuss Substance Abuse and Treatment at 2015 Oscars 2Health News:The Leukemia & Lymphoma Society’s Oregon and SW Washington Chapter Kicks Off Their Eleventh Annual Man, Woman & Student of the Year Campaign 2Health News:The Leukemia & Lymphoma Society’s Oregon and SW Washington Chapter Kicks Off Their Eleventh Annual Man, Woman & Student of the Year Campaign 3Health News:1% For the Planet Asks Consumers to “Know Your Source” 2Health News:TU-Automotive: Wawanesa Insurance to Discuss How UBI Can Produce Happy, Loyal Customers 2Health News:ASHA Applauds Launch of New WHO Campaign 2
... program continues momentum in North ... ... nation,s largest effort to reward physicians for,delivering high-quality care, announced today that ... BCBSNC,and the North Carolina State Health Plan are collaborating in a three-year,pilot ...
... WellPoint,NextRx, the nation,s largest health plan-owned pharmacy benefits manager,(PBM) ... Idaho to serve,as the pharmacy benefits manager for their ... of Idaho, an independent licensee of the Blue,Cross Blue ... contract,will extend this agreement for an additional five years., ...
... to Provide ... for Their Families, CHICAGO, May 7 Mother,s Day is ... gatherings and gifts,and to honor those who give so much to their families ... of those mothers who,live in poverty and need the assistance of programs offered ...
... sales $50.8 million, up 25% versus year ago on operating basis ... high commodity costs - Net loss $1.2 million, includes ... 30% growth in net sales on operating basis (1), PARAMUS, ... announced its results for the first quarter ended,March 31, 2008. The ...
... activity in brain,s reward centers , , WEDNESDAY, May 7 ... that a gut hormone known for its appetite-promoting powers ... make food look more tasty and irresistible. , The ... this hormone,s so-called "hedonic effect" on the senses unfolds ...
... as Steno, has just been sequenced. The results reveal ... The research was carried out by scientists at the ... of Bristol. , Understanding the genome of this ... this particularly resistant organism. The paper will be published ...
Cached Medicine News:Health News:Blue Cross and Blue Shield of North Carolina Achieves Bridges to Excellence Certification 2Health News:Blue Cross and Blue Shield of North Carolina Achieves Bridges to Excellence Certification 3Health News:WellPoint NextRx Announces New Agreement With Blue Cross of Idaho 2Health News:Catholic Charities Calls for Increased Support of Mothers in Need: 2Health News:Smart Balance Announces 2008 First-Quarter Results 2Health News:Smart Balance Announces 2008 First-Quarter Results 3Health News:Smart Balance Announces 2008 First-Quarter Results 4Health News:Smart Balance Announces 2008 First-Quarter Results 5Health News:Smart Balance Announces 2008 First-Quarter Results 6Health News:Smart Balance Announces 2008 First-Quarter Results 7Health News:Smart Balance Announces 2008 First-Quarter Results 8Health News:Smart Balance Announces 2008 First-Quarter Results 9Health News:Smart Balance Announces 2008 First-Quarter Results 10Health News:Smart Balance Announces 2008 First-Quarter Results 11Health News:Smart Balance Announces 2008 First-Quarter Results 12Health News:Hunger Hormone Makes Food Look More Tasty 2Health News:Hunger Hormone Makes Food Look More Tasty 3Health News:Superbug genome sequenced 2
... The SleepStyle 200 series offers ... integrated CPAP models. The design delivers ... patients. Performance features promote results in ... care. The strongest differentiator in the ...
... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
... REMstar Plus with C-Flex ... controls, and the comfort of ... the REMstar Plus with C-Flex ... to deliver sleep therapy by ...
Medicine Products: